BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 33524167)

  • 21. Mastocytosis and related entities: a practical roadmap.
    Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V
    Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
    Singh A; Al-Kali A; Begna KH; Litzow MR; Larsen JT; Sher T; Abdelmagid MG; Farrukh F; Reichard KK; Gangat N; Pardanani A; Tefferi A
    Am J Hematol; 2022 May; 97(5):630-637. PubMed ID: 35156231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relevant updates in systemic mastocytosis.
    Coltoff A; Mascarenhas J
    Leuk Res; 2019 Jun; 81():10-18. PubMed ID: 30978435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases.
    Shah S; Pardanani A; Elala YC; Lasho TL; Patnaik MM; Reichard KK; Hanson CA; Ketterling RP; Tefferi A
    Am J Hematol; 2018 Dec; 93(12):1461-1466. PubMed ID: 30152525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
    Nedoszytko B; Arock M; Lyons JJ; Bachelot G; Schwartz LB; Reiter A; Jawhar M; Schwaab J; Lange M; Greiner G; Hoermann G; Niedoszytko M; Metcalfe DD; Valent P
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
    Shomali W; Gotlib J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
    Valent P; Akin C; Arock M; Gleixner KV; Greinix H; Hermine O; Horny HP; Ivanov D; Orfao A; Rabitsch W; Reiter A; Schulenburg A; Sotlar K; Sperr WR; Ustun C
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
    Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival.
    Pardanani A; Lasho T; Elala Y; Wassie E; Finke C; Reichard KK; Chen D; Hanson CA; Ketterling RP; Tefferi A
    Am J Hematol; 2016 Sep; 91(9):888-93. PubMed ID: 27214377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.
    Horny HP; Sotlar K; Sperr WR; Valent P
    J Clin Pathol; 2004 Jun; 57(6):604-8. PubMed ID: 15166264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis.
    Reichard KK; Chen D; Pardanani A; McClure RF; Howard MT; Kurtin PJ; Wood AJ; Ketterling RP; King RL; He R; Morice WG; Hanson CA
    Am J Clin Pathol; 2015 Sep; 144(3):493-502. PubMed ID: 26276780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.
    Morgado JM; Perbellini O; Johnson RC; Teodósio C; Matito A; Álvarez-Twose I; Bonadonna P; Zamò A; Jara-Acevedo M; Mayado A; Garcia-Montero A; Mollejo M; George TI; Zanotti R; Orfao A; Escribano L; Sánchez-Muñoz L
    Histopathology; 2013 Dec; 63(6):780-7. PubMed ID: 24111625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy.
    Valent P; Akin C; Sperr WR; Horny HP; Arock M; Metcalfe DD; Galli SJ
    Annu Rev Pathol; 2023 Jan; 18():361-386. PubMed ID: 36270293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.
    Valent P; Hartmann K; Schwaab J; Alvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Carter MC; Hoermann G; Sperr WR; Butterfield JH; Ustun C; Zanotti R; Radia DH; Castells M; Triggiani M; Schwartz LB; Orfao A; George TI; Sotlar K; Gotlib J; Reiter A; Horny HP; Arock M; Akin C; Metcalfe DD
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1999-2012.e6. PubMed ID: 35342031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
    Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
    Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?
    Akin C; Arock M; Valent P
    J Allergy Clin Immunol; 2022 Jun; 149(6):1912-1918. PubMed ID: 35487307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Target Therapies for Systemic Mastocytosis: An Update.
    Sciumè M; De Magistris C; Galli N; Ferretti E; Milesi G; De Roberto P; Fabris S; Grifoni FI
    Pharmaceuticals (Basel); 2022 Jun; 15(6):. PubMed ID: 35745657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child.
    Zheng Y; Nong L; Liang L; Wang W; Li T
    Diagn Pathol; 2018 Feb; 13(1):14. PubMed ID: 29458385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders.
    Perbellini O; Zamò A; Colarossi S; Zampieri F; Zoppi F; Bonadonna P; Schena D; Artuso A; Martinelli G; Chilosi M; Pizzolo G; Zanotti R
    Cytometry B Clin Cytom; 2011 Nov; 80(6):362-8. PubMed ID: 21656905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis.
    Berezowska S; Flaig MJ; Ruëff F; Walz C; Haferlach T; Krokowski M; Kerler R; Petat-Dutter K; Horny HP; Sotlar K
    Mod Pathol; 2014 Jan; 27(1):19-29. PubMed ID: 23807778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.